Why the study?
What is the dose-response relationship and heritability of LDL-C reduction with statin therapy in a real-world population?
What is the dose-response relationship and heritability of LDL-C reduction with statin therapy in a real-world population?
Real-world electronic health record data confirms the 'rule of 6%' for statin LDL-C dose-response and demonstrates that clinical factors, rather than strong heritability, predict LDL-C reduction.
Statin LDL-C dose response aligns with trial data in real-world multiethnic users; modest heritability leaves genetic determinants open for further study.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) response to statin therapy has not been fully elucidated in real-world populations. The primary objective of this study was to characterize statin LDL-C dose-response and its heritability in a large, multiethnic population of statin users. METHODS: We determined the effect of statin dosing on lipid measures utilizing electronic health records in 33 139 statin users from the Kaiser Permanente GERA cohort (Genetic Epidemiology Research on Adult Health and Aging). The relationship between statin defined daily dose and lipid parameter response (percent change) was determined. Statin type, sex, age, smoking status, diabetes mellitus, and East Asian race/ethnicity were significant independent predictors of statin-induced changes in LDL-C. Based on a variance-component method within the subset of statin users who had at least 1 first-degree relative who was also a statin user (n=1036), heritability of statin LDL-C response was estimated at 11.7% (SE, 8.6%; P=0.087). CONCLUSIONS: Using electronic health record data, we observed a statin LDL-C dose-response consistent with the rule of 6% from prior clinical trial data. Clinical and demographic predictors of statin LDL-C response exhibited highly significant but modest effects. Finally, statin-induced changes in LDL-C were not found to be strongly inherited. Ultimately, these findings demonstrate (1) the utility of electronic health records as a reliable source to generate robust phenotypes for pharmacogenomic research and (2) the potential role of statin precision medicine in lipid management.
No takes yet. Share an insight, caveat, or question.
Oni‐Orisan et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: